Korean Biopharma Today And Tomorrow: M&A, Investment, Governance
Policies, Family Management In Spotlight
Experts shared views at a recent conference in Seoul on how the Korean biopharma industry has evolved and what needs to be done to move forward in the next 10 years. Policy efficiency and family ownership in the sector came in for particular scrutiny, with some calling for sweeping changes.
